CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 358 enrolled
Drug / intervention
Prostaglandin Analogue -Containing IOP-Lowering Therapydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01735214
NCT01735214N/ACompleted
CompareCT.gov

An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments

Allergan·observational·Posted Nov 28, 2012·Updated Apr 18, 2019

In Brief

An observational study evaluating Prostaglandin Analogue -Containing IOP-Lowering Therapy for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 358 participants across 1 site.

Detailed Summary

This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). The decision to change medications lies with the physician according to their standard practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 28, 2012
Enrollment StartMar 7, 2013
Primary CompletionApr 10, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.6 years ago

Interventions

Prostaglandin Analogue -Containing IOP-Lowering Therapydrug

Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.